Results 61 to 70 of about 165,287 (121)

Alfa-Cakes-Fabrik G.m.b.H, Radebeul-Dresden, Befreiungshalle.

ALFA-CAKES-FABRIK G.M.B.H, RADEBEUL-DRESDEN, BEFREIUNGSHALLE. Alfa-Cakes-Fabrik G.m.b.H, Radebeul-Dresden, Befreiungshalle. ( -
Alfa-Cakes-Fabrik G.m.b.H.
core   +1 more source

Apresentação

, 2001
Alfa, Revista
core   +4 more sources

1973. Domenico Rea a Alfa Romeo - Alfa sud

, 1973
Rea, Domenico, Alfa Romeo - Alfasud
core   +1 more source

Psychiatric manifestations in Neuronal ceroid lipofuscinoses. [PDF]

Orphanet J Rare Dis
Della Vecchia S, Simonati A, Marchese M, Berloffa S, Kohlschütter A, Santorelli FM.   +5 more
europepmc   +1 more source

First case of use of cerliponase alfa in a child with neuronal ceroid lipofuscinosis type 2 in Bahia

Arquivos de Neuro-Psiquiatria
Érica Otoni Pereira Miranda, Lukas Santos Freire, Giovana Andrade de Oliveira, Ícaro Giovani Barros Carregosa, Rebeca Lima de Almeida Santos, Qesya Rodrigues Ferreira, Odivan de Souza Lopes, Emmanuel Santos Trindade, Lorena Tanajura Oliveira   +8 more
openaire   +1 more source

PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy. [PDF]

NeuroImmune Pharm Ther
Chandra S, Pahan K.
europepmc   +1 more source

Risk management plans and drug safety in Canada: A cross-sectional study. [PDF]

Int J Risk Saf Med
Lexchin J.
europepmc   +1 more source

Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom. [PDF]

Orphanet J Rare Dis
Mole SE, Gissen P, Nordstrom S, Wait S, Allen L, Antonini M, Brownnutt L, Brown R, Cole B, Gibbon F, Henderson RH, Kenrick S, Sisic Z, Thompson B, Nightingale J.   +14 more
europepmc   +1 more source

Rarely listed essential medicines in 158 national lists. [PDF]

J Pharm Policy Pract
Ul Haq MZ, Heredia C, Rizvi A, Workentin A, Persaud N.   +4 more
europepmc   +1 more source

Relação dos livros recebidos em intercâmbio com a revista Alfa [PDF]

, 2001
Revista Alfa, Alfa, Revista
core   +2 more sources